Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Capecitabine in combination with Neratinib in patients with Invasive Breast Carcinoma.

Statements

Source and description
Nerlynx (neratinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.